311
have been decreasing, and these positive changes may play a role in increased utilization and awareness of lipid decreasing medications [101]. The incidence of hyperlipidemia was 20% in adolescents and children in the USA during the period of
1999–2012 [102].
Insulin Resistance
Regarding MetS, it is considered that components of MetS originate from insulin
resistance. Abnormal expression of gluconeogenic enzymes causes insulin resistance, which is represented by defects in glucose tolerance and enhanced level of
fasting glucose. Hyperinsulinemia occurred when they start to produce further insulin release in the metabolic state. Transcription factors such as Srebp-1c in the liver
are then stimulated by hyperinsulinemia, which causes hepatic steatosis and hypertriglyceridemia [103]. Moreover, the increased insulin production and secretion
may cause the collapse and death of pancreatic β-cells and initialize T2D onset. The
well-known insulin resistance form is linked with adipose tissue dysfunction and
abdominal, representing a significant role of obesity in MetS.
In type 2 diabetes many cases were presented with insulin resistance. Due to
satisfactory increased biogenesis and release of insulin and production of pancreatic
β-cell mass, the hyperglycemia is not developed insulin resistance individuals, for
example, in obese subjects, 2–5 times more insulin secretion occurs in glucose
response, while in athletes 2–5 times less insulin is secreted. β-cell mass and functional adaptation are counteracted to insulin resistance which occurs during the
period of puberty and pregnancy depending upon maternal hormones and sex [104,
105]. Therefore, insulin sensitivity controls function of β-cell; insulin-resistant subjects, regardless they are lean or obese, show a better response to insulin and less
insulin clearance than individuals sensitive to insulin. The adaptation to the β-cell
must fail to lead insulin resistance to T2D [106]. Hypertrophy and proliferation of
existing cells regulate. The ability of β-cell mass and its function is increased by
glucose, free fatty acids, metabolic hormones, and neuronal, however abnormal
increase in glucose and lipids causes β-cell death and predisposes to T2DM [107].
In metabolic signal stability of pancreatic β-cells to assimilate responses to alter
insulin sensitivity probably involves enhanced metabolism. These comprise of adipocytes signaling molecules (e.g., NEFAs signaling via GPR40) and fatty acylCoAs that stimulate the release of insulin through protein kinase C (PKC) and
exocytotic machinery. Leptin, adiponectin, and proinflammatory cytokines, for
example, monocyte chemoattractant protein (MCP-1) and TNFα, IL-6 from macrophages and other cells infiltrating adipose tissue that also play a role [107]. Glucagon
is produced and released by pancreatic α-cells. Thus alternation in the function of
pancreatic alpha cells also plays a role in T2D. The pancreatic alpha cell mass is not
increased in T2D, causing enhanced α-to-β cell ratio; this altered ratio also contributes to higher plasma levels of glucagon and therefore to hypoglycemia [106]. For
this reason, while β-cells are healthy, their adaptive responses counter balance
18 Role of Perfluoroalkyl Substances as EDCs in Metabolic Disorders
have been decreasing, and these positive changes may play a role in increased utilization and awareness of lipid decreasing medications [101]. The incidence of hyperlipidemia was 20% in adolescents and children in the USA during the period of
1999–2012 [102].
Insulin Resistance
Regarding MetS, it is considered that components of MetS originate from insulin
resistance. Abnormal expression of gluconeogenic enzymes causes insulin resistance, which is represented by defects in glucose tolerance and enhanced level of
fasting glucose. Hyperinsulinemia occurred when they start to produce further insulin release in the metabolic state. Transcription factors such as Srebp-1c in the liver
are then stimulated by hyperinsulinemia, which causes hepatic steatosis and hypertriglyceridemia [103]. Moreover, the increased insulin production and secretion
may cause the collapse and death of pancreatic β-cells and initialize T2D onset. The
well-known insulin resistance form is linked with adipose tissue dysfunction and
abdominal, representing a significant role of obesity in MetS.
In type 2 diabetes many cases were presented with insulin resistance. Due to
satisfactory increased biogenesis and release of insulin and production of pancreatic
β-cell mass, the hyperglycemia is not developed insulin resistance individuals, for
example, in obese subjects, 2–5 times more insulin secretion occurs in glucose
response, while in athletes 2–5 times less insulin is secreted. β-cell mass and functional adaptation are counteracted to insulin resistance which occurs during the
period of puberty and pregnancy depending upon maternal hormones and sex [104,
105]. Therefore, insulin sensitivity controls function of β-cell; insulin-resistant subjects, regardless they are lean or obese, show a better response to insulin and less
insulin clearance than individuals sensitive to insulin. The adaptation to the β-cell
must fail to lead insulin resistance to T2D [106]. Hypertrophy and proliferation of
existing cells regulate. The ability of β-cell mass and its function is increased by
glucose, free fatty acids, metabolic hormones, and neuronal, however abnormal
increase in glucose and lipids causes β-cell death and predisposes to T2DM [107].
In metabolic signal stability of pancreatic β-cells to assimilate responses to alter
insulin sensitivity probably involves enhanced metabolism. These comprise of adipocytes signaling molecules (e.g., NEFAs signaling via GPR40) and fatty acylCoAs that stimulate the release of insulin through protein kinase C (PKC) and
exocytotic machinery. Leptin, adiponectin, and proinflammatory cytokines, for
example, monocyte chemoattractant protein (MCP-1) and TNFα, IL-6 from macrophages and other cells infiltrating adipose tissue that also play a role [107]. Glucagon
is produced and released by pancreatic α-cells. Thus alternation in the function of
pancreatic alpha cells also plays a role in T2D. The pancreatic alpha cell mass is not
increased in T2D, causing enhanced α-to-β cell ratio; this altered ratio also contributes to higher plasma levels of glucagon and therefore to hypoglycemia [106]. For
this reason, while β-cells are healthy, their adaptive responses counter balance
18 Role of Perfluoroalkyl Substances as EDCs in Metabolic Disorders